Analyst Expectations For Myriad Genetics's Future
Analyst Expectations For Myriad Genetics's Future
萬基遺傳的未來分析師預期
The perception of Myriad Genetics by financial experts is analyzed through recent...7 analysts have shared their evaluations of Myriad Genetics (NASDAQ:MYGN) during the recent three months, expressing a mix of bullish and bearish perspectives.
在最近3個月中，有7位分析師對Myriad Genetics(NASDAQ:MYGN)進行了評價，表達了看好和看淡的不同觀點。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $30.0, a high estimate of $35.00, and a low estimate of $20.00. Observing a 17.65% increase, the current average has risen from the previous average price target of $25.50.
分析師的12個月目標股價揭示了平均目標爲$30.0，高估爲$35.00，低估爲$20.00。觀察到17.65%的增長，當前平均價格較之前的平均目標價$25.50有所上升。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析師評級：全面解析
The perception of Myriad Genetics by financial experts is analyzed through recent...
通過最近的分析師行動，分...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間